• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SF3A2 通过 MKRN1 的选择性剪接促进三阴性乳腺癌的进展和顺铂耐药性。

SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1.

机构信息

Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China.

Cancer Institute, Shanghai Medical College, Fudan University, Shanghai 200032, China.

出版信息

Sci Adv. 2024 Apr 5;10(14):eadj4009. doi: 10.1126/sciadv.adj4009. Epub 2024 Apr 3.

DOI:10.1126/sciadv.adj4009
PMID:38569025
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10990288/
Abstract

Triple-negative breast cancer (TNBC) is the deadliest subtype of breast cancer owing to the lack of effective therapeutic targets. Splicing factor 3a subunit 2 (SF3A2), a poorly defined splicing factor, was notably elevated in TNBC tissues and promoted TNBC progression, as confirmed by cell proliferation, colony formation, transwell migration, and invasion assays. Mechanistic investigations revealed that E3 ubiquitin-protein ligase UBR5 promoted the ubiquitination-dependent degradation of SF3A2, which in turn regulated UBR5, thus forming a feedback loop to balance these two oncoproteins. Moreover, SF3A2 accelerated TNBC progression by, at least in part, specifically regulating the alternative splicing of makorin ring finger protein 1 () and promoting the expression of the dominant and oncogenic isoform, . Furthermore, SF3A2 participated in the regulation of both extrinsic and intrinsic apoptosis, leading to cisplatin resistance in TNBC cells. Collectively, these findings reveal a previously unknown role of SF3A2 in TNBC progression and cisplatin resistance, highlighting SF3A2 as a potential therapeutic target for patients with TNBC.

摘要

三阴性乳腺癌(TNBC)是乳腺癌中最致命的亚型,因为缺乏有效的治疗靶点。剪接因子 3a 亚基 2(SF3A2)是一种定义不明确的剪接因子,在 TNBC 组织中明显升高,并通过细胞增殖、集落形成、transwell 迁移和侵袭实验证实促进了 TNBC 的进展。机制研究表明,E3 泛素蛋白连接酶 UBR5 促进 SF3A2 的泛素化依赖性降解,而 SF3A2 反过来又调节 UBR5,从而形成一个反馈环来平衡这两种致癌蛋白。此外,SF3A2 通过至少部分地特异性调节 makorin 环指蛋白 1()的可变剪接并促进显性致癌同工型的表达,来加速 TNBC 的进展。此外,SF3A2 参与了外在和内在凋亡的调节,导致 TNBC 细胞对顺铂产生耐药性。总的来说,这些发现揭示了 SF3A2 在 TNBC 进展和顺铂耐药性中的一个以前未知的作用,突出了 SF3A2 作为 TNBC 患者潜在治疗靶点的可能性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8088/10990288/1dee145bf8b2/sciadv.adj4009-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8088/10990288/7635ea01fbc2/sciadv.adj4009-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8088/10990288/58e93eeb1c6a/sciadv.adj4009-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8088/10990288/8b49a9161716/sciadv.adj4009-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8088/10990288/3e9b21aa6c58/sciadv.adj4009-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8088/10990288/fd44802428f7/sciadv.adj4009-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8088/10990288/ef4b28fc524b/sciadv.adj4009-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8088/10990288/1dee145bf8b2/sciadv.adj4009-f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8088/10990288/7635ea01fbc2/sciadv.adj4009-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8088/10990288/58e93eeb1c6a/sciadv.adj4009-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8088/10990288/8b49a9161716/sciadv.adj4009-f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8088/10990288/3e9b21aa6c58/sciadv.adj4009-f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8088/10990288/fd44802428f7/sciadv.adj4009-f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8088/10990288/ef4b28fc524b/sciadv.adj4009-f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8088/10990288/1dee145bf8b2/sciadv.adj4009-f7.jpg

相似文献

1
SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1.SF3A2 通过 MKRN1 的选择性剪接促进三阴性乳腺癌的进展和顺铂耐药性。
Sci Adv. 2024 Apr 5;10(14):eadj4009. doi: 10.1126/sciadv.adj4009. Epub 2024 Apr 3.
2
TRA2A Promoted Paclitaxel Resistance and Tumor Progression in Triple-Negative Breast Cancers via Regulating Alternative Splicing.TRA2A 通过调控可变剪接促进三阴性乳腺癌的紫杉醇耐药和肿瘤进展。
Mol Cancer Ther. 2017 Jul;16(7):1377-1388. doi: 10.1158/1535-7163.MCT-17-0026. Epub 2017 Apr 17.
3
CPSF4-mediated regulation of alternative splicing of HMG20B facilitates the progression of triple-negative breast cancer.CPSF4介导的HMG20B可变剪接调控促进三阴性乳腺癌进展。
J Transl Med. 2024 Dec 27;22(1):1149. doi: 10.1186/s12967-024-06004-x.
4
The oncogenic kinase NEK2 regulates an RBFOX2-dependent pro-mesenchymal splicing program in triple-negative breast cancer cells.致癌激酶 NEK2 调节三阴性乳腺癌细胞中 RBFOX2 依赖性的促间质剪接程序。
J Exp Clin Cancer Res. 2021 Dec 20;40(1):397. doi: 10.1186/s13046-021-02210-3.
5
ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells.ISL1 促进三阴性乳腺癌细胞的癌症进展并抑制顺铂敏感性。
Int J Mol Med. 2018 Nov;42(5):2343-2352. doi: 10.3892/ijmm.2018.3842. Epub 2018 Aug 27.
6
Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer.蛋白磷酸酶 1 亚基 PPP1R14B 通过稳定 STMN1 促进三阴性乳腺癌的进展和紫杉醇耐药性。
Cancer Res. 2023 Feb 3;83(3):471-484. doi: 10.1158/0008-5472.CAN-22-2709.
7
Chaperonin-containing TCP1 subunit 6A inhibition via TRIM21-mediated K48-linked ubiquitination suppresses triple-negative breast cancer progression through the AKT signalling pathway.伴侣蛋白包含的 TCP1 亚基 6A 通过 TRIM21 介导的 K48 连接泛素化抑制作用抑制三阴性乳腺癌进展,通过 AKT 信号通路。
Clin Transl Med. 2024 Nov;14(11):e70097. doi: 10.1002/ctm2.70097.
8
[Hydnocarpin inhibits malignant progression of triple negative breast cancer via CNOT4-mediated ubiquitination and degradation of YAP].[大风子素通过CNOT4介导的YAP泛素化和降解抑制三阴性乳腺癌的恶性进展]
Zhongguo Zhong Yao Za Zhi. 2023 Aug;48(16):4483-4492. doi: 10.19540/j.cnki.cjcmm.20230510.706.
9
SNRPB2 promotes triple-negative breast cancer progression by controlling alternative splicing of MDM4 pre-mRNA.SNRPB2通过控制MDM4前体mRNA的可变剪接促进三阴性乳腺癌进展。
Cancer Sci. 2024 Dec;115(12):3915-3927. doi: 10.1111/cas.16356. Epub 2024 Sep 27.
10
E3 ubiquitin ligase RNF180 reduces sensitivity of triple-negative breast cancer cells to Gefitinib by downregulating RAD51.E3 泛素连接酶 RNF180 通过下调 RAD51 降低三阴性乳腺癌细胞对吉非替尼的敏感性。
Chem Biol Interact. 2022 Feb 25;354:109798. doi: 10.1016/j.cbi.2022.109798. Epub 2022 Jan 6.

引用本文的文献

1
MKRN1 degrades AGC1 to trigger chemotherapy resistance of colorectal Cancer.MKRN1降解AGC1以引发结直肠癌的化疗耐药性。
Mol Med. 2025 Jul 28;31(1):268. doi: 10.1186/s10020-025-01287-2.
2
Ursolic acid suppresses triple-negative breast cancer progression through mediating FABP4/PPARG pathway.熊果酸通过介导脂肪酸结合蛋白4/过氧化物酶体增殖物激活受体γ途径抑制三阴性乳腺癌进展。
Eur J Med Res. 2025 Jul 2;30(1):550. doi: 10.1186/s40001-025-02794-y.
3
Spliceosomal GTPase EFTUD2 mediates DDX41 intron retention to promote the malignant progression of ovarian cancer.

本文引用的文献

1
Deubiquitinase OTUD6A promotes breast cancer progression by increasing TopBP1 stability and rendering tumor cells resistant to DNA-damaging therapy.去泛素化酶 OTUD6A 通过增加 TopBP1 的稳定性并使肿瘤细胞对 DNA 损伤治疗产生抗性,促进乳腺癌的进展。
Cell Death Differ. 2022 Dec;29(12):2531-2544. doi: 10.1038/s41418-022-01036-6. Epub 2022 Jun 29.
2
UBR5 targets tumor suppressor CDC73 proteolytically to promote aggressive breast cancer.UBR5 通过靶向肿瘤抑制因子 CDC73 的蛋白水解作用来促进侵袭性乳腺癌。
Cell Death Dis. 2022 May 12;13(5):451. doi: 10.1038/s41419-022-04914-6.
3
Chromatin complexes subunit BAP18 promotes triple-negative breast cancer progression through transcriptional activation of oncogene S100A9.
剪接体GTP酶EFTUD2介导DDX41内含子保留以促进卵巢癌的恶性进展。
Br J Cancer. 2025 Jun 24. doi: 10.1038/s41416-025-03079-1.
4
Photothermal therapeutic effects and biosafety of a carbon nanoparticles-Fe(ii) complex for triple-negative breast cancer.碳纳米颗粒 - 亚铁(II)配合物对三阴性乳腺癌的光热治疗效果及生物安全性
RSC Adv. 2025 Jun 10;15(25):19665-19675. doi: 10.1039/d5ra03041b.
5
Single-cell and transcriptome analyses revealed CTHRC1 a potential therapeutic target mediating invasion and tumor microenvironment in TNBC: experimental validation.单细胞和转录组分析揭示CTHRC1是介导三阴性乳腺癌侵袭和肿瘤微环境的潜在治疗靶点:实验验证
Front Immunol. 2025 Mar 11;16:1534981. doi: 10.3389/fimmu.2025.1534981. eCollection 2025.
6
Carboplatin-resistance-related DNA damage repair prognostic gene signature and its association with immune infiltration in breast cancer.与卡铂耐药相关的DNA损伤修复预后基因特征及其与乳腺癌免疫浸润的关联
Front Immunol. 2025 Jan 29;16:1522149. doi: 10.3389/fimmu.2025.1522149. eCollection 2025.
7
Targeting RNA splicing modulation: new perspectives for anticancer strategy?靶向RNA剪接调控:抗癌策略的新视角?
J Exp Clin Cancer Res. 2025 Jan 30;44(1):32. doi: 10.1186/s13046-025-03279-w.
8
Interaction of STIL with FOXM1 regulates SF3A3 transcription in the hepatocellular carcinoma development.STIL与FOXM1的相互作用在肝细胞癌发展过程中调节SF3A3转录。
Cell Div. 2025 Jan 17;20(1):1. doi: 10.1186/s13008-025-00142-4.
9
Mechanisms of RNA alternative splicing dysregulation in triple-negative breast cancer.三阴性乳腺癌中RNA可变剪接失调的机制
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 Jul 28;49(7):1143-1154. doi: 10.11817/j.issn.1672-7347.2024.240434.
10
SNRNP70 regulates the splicing of CD55 to promote osteosarcoma progression.小核核糖核蛋白70(SNRNP70)调节CD55的剪接以促进骨肉瘤进展。
JCI Insight. 2024 Dec 20;9(24):e185269. doi: 10.1172/jci.insight.185269.
染色质复合物亚基 BAP18 通过转录激活癌基因 S100A9 促进三阴性乳腺癌的进展。
Cell Death Dis. 2022 Apr 28;13(4):408. doi: 10.1038/s41419-022-04785-x.
4
Targeted protein degradation: mechanisms, strategies and application.靶向蛋白降解:机制、策略与应用。
Signal Transduct Target Ther. 2022 Apr 4;7(1):113. doi: 10.1038/s41392-022-00966-4.
5
Proteome-centric cross-omics characterization and integrated network analyses of triple-negative breast cancer.基于蛋白质组学的三阴性乳腺癌的跨组学特征分析及综合网络分析。
Cell Rep. 2022 Mar 1;38(9):110460. doi: 10.1016/j.celrep.2022.110460.
6
Platinum-based systematic therapy in triple-negative breast cancer.三阴性乳腺癌的铂类全身治疗
Biochim Biophys Acta Rev Cancer. 2022 Jan;1877(1):188678. doi: 10.1016/j.bbcan.2022.188678. Epub 2022 Jan 10.
7
Targeting DNA Damage Response and Repair to Enhance Therapeutic Index in Cisplatin-Based Cancer Treatment.针对 DNA 损伤反应和修复以提高顺铂类癌症治疗的治疗指数。
Int J Mol Sci. 2021 Jul 30;22(15):8199. doi: 10.3390/ijms22158199.
8
Alternative splicing and cancer: a systematic review.可变剪接与癌症:系统性综述。
Signal Transduct Target Ther. 2021 Feb 24;6(1):78. doi: 10.1038/s41392-021-00486-7.
9
The role of alternative splicing in cancer: From oncogenesis to drug resistance.可变剪接在癌症中的作用:从致癌作用到耐药性。
Drug Resist Updat. 2020 Dec;53:100728. doi: 10.1016/j.drup.2020.100728. Epub 2020 Sep 28.
10
Roles and mechanisms of alternative splicing in cancer - implications for care.剪接在癌症中的作用和机制——对治疗的影响。
Nat Rev Clin Oncol. 2020 Aug;17(8):457-474. doi: 10.1038/s41571-020-0350-x. Epub 2020 Apr 17.